Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the efficacy and safety of Aptalis' (formerly Eurand)
pancreatic enzyme product (PEP) microtabs in pediatric participants under age 7 with cystic
fibrosis (CF) and exocrine pancreatic insufficiency (EPI).